Nervgen Pharma Corp. SEC filings NGEN
Nervgen Pharma Corp. has 41 filings in SEC EDGAR's recent list, going back to Sep 20, 2018. Its latest annual report, Form 40-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 25, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-X | Form f-x | May 26, 2026 | — |
| F-10 | Filing | May 26, 2026 | — |
| S-8 | Employee stock plan registration | May 7, 2026 | — |
| S-8 | Employee stock plan registration | Jan 23, 2026 | — |
| F-10/A | Filing | Jan 7, 2026 | — |
| F-X | Form f-x | Dec 17, 2025 | — |
| F-10 | Filing | Dec 17, 2025 | — |
Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGEN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1751912
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.